Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Wynendaele

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Forum (Genoa, Italy)|September 30, 1999
Neoadjuvant/primary chemotherapy in cancer treatment: what advantage?W Wynendaele, A T van Oosterom
Pharmacy World & Science : PWS|February 11, 1999
Angiogenesis: possibilities for therapeutic interventionsW Wynendaele, A T van Oosterom, A Pawinski, et al.
Clinical and Laboratory Haematology|April 25, 2006
Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcomeH Castryck, M van den Driessche, A Hagemeijer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral bloodJ Aerts, W Wynendaele, R Paridaens, et al.
Breast Cancer Research and Treatment|July 24, 2010
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancerH Wildiers, C Fontaine, P Vuylsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?W Wynendaele, R Derua, M F Hoylaerts, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumoursF A L M Eskens, H Dumez, R Hoekstra, et al.
British Journal of Cancer|November 11, 2010
Cancer and renal insufficiency results of the BIRMA studyN Janus, V Launay-Vacher, E Byloos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic studyH J Groen, E G de Vries, W Wynendaele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2010
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancerH Wildiers, P Neven, M R Christiaens, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Forum (Genoa, Italy)|September 30, 1999
Neoadjuvant/primary chemotherapy in cancer treatment: what advantage?W Wynendaele, A T van Oosterom
Pharmacy World & Science : PWS|February 11, 1999
Angiogenesis: possibilities for therapeutic interventionsW Wynendaele, A T van Oosterom, A Pawinski, et al.
Clinical and Laboratory Haematology|April 25, 2006
Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcomeH Castryck, M van den Driessche, A Hagemeijer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral bloodJ Aerts, W Wynendaele, R Paridaens, et al.
Breast Cancer Research and Treatment|July 24, 2010
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancerH Wildiers, C Fontaine, P Vuylsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?W Wynendaele, R Derua, M F Hoylaerts, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2003
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumoursF A L M Eskens, H Dumez, R Hoekstra, et al.
British Journal of Cancer|November 11, 2010
Cancer and renal insufficiency results of the BIRMA studyN Janus, V Launay-Vacher, E Byloos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic studyH J Groen, E G de Vries, W Wynendaele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2010
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancerH Wildiers, P Neven, M R Christiaens, et al.
Pageof 2